Male Infertility
Male Infertility
References
- 2023 Canadian Urological Association Guideline: Evaluation and Management of Azoospermia — Canadian Urological Association Journal, Canadian Urological Association (Flannigan R, Tadayon Najafabadi B, Violette PD, Jarvi K, Patel P, Bach PV, Domes T, Zini A, Grober E, Mak V, Fischer MA, Chan P, Lo K, Chow V, Wu C, Grantmyre J, Patry G, Schlegel PN, Roberts M). Can Urol Assoc J 2023;17(8):228-40
- Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part I — Fertility and Sterility, American Urological Association / American Society for Reproductive Medicine (Schlegel PN, Sigman M, Collura B, et al.). Fertil Steril 2021;115(1):54-61
- Report on Varicocele and Infertility: A Committee Opinion — Fertility and Sterility, Practice Committee of the American Society for Reproductive Medicine and the Society for Male Reproduction and Urology. Fertil Steril 2014;102(6):1556-1560
- Optimizing Natural Fertility: A Committee Opinion (2022) — Fertility and Sterility, Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2022;117(1):53-63
- Physical, Psychological and Biochemical Recovery From Anabolic Steroid-Induced Hypogonadism: A Scoping Review — Endocrine Connections (Solanki P, Eu B, Smith J, Allan C, Lee K). Endocr Connect 2023;12(12):e230358
- The Sixth Edition of the WHO Manual for Human Semen Analysis: A Critical Review and SWOT Analysis — Life (Basel) (Boitrelle F, et al.). Life (Basel) 2021;11(12):1368
- Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part II — Fertility and Sterility, American Urological Association / American Society for Reproductive Medicine (Schlegel PN, Sigman M, Collura B, et al.). Fertil Steril 2021;115(1):62-69
- Clomiphene Citrate for Male Infertility: A Systematic Review and Meta-Analysis — Andrology (Huijben M, et al.). Andrology 2023;11(5):987-996
Clinical Snapshot
Male infertility refers to the male partner's inability to contribute to a pregnancy after 12 months of regular, unprotected intercourse — the same duration-based trigger used to evaluate the female partner, because infertility is properly investigated as a couple-level problem from the outset rather than a female-only one.[1] Roughly 15% of Canadian couples experience infertility in a given year, and a male factor is implicated in close to half of these cases — solely responsible in about 20%, and contributing alongside a female factor in another 30-40%.[1]
This is a genuinely important reframing point: fertility investigation has historically been female-centric, with the male partner's evaluation sometimes deferred until the female workup is "exhausted." A semen analysis is simple, inexpensive, and highly informative, and should be obtained early — in parallel with the female partner's workup, not after it.[2]
What this chapter does, and honestly does not, cover
Male infertility workup and treatment is substantially specialist-managed — urology and andrology territory. This chapter is scoped to what a community or specialty pharmacist can genuinely add: understanding the basic diagnostic workup (semen analysis, hormone panel) well enough to support a patient navigating it and to recognize which broad category a result points toward; counselling on the fertility-relevant medications pharmacists actually dispense for this condition — clomiphene citrate, letrozole, and anastrozole, repurposed off-label for confirmed hypogonadotropic hypogonadism, and the gonadotropin injections sometimes added alongside them; recognizing exogenous testosterone and anabolic-androgenic steroid use as a genuinely common and under-recognized iatrogenic cause of male infertility; reinforcing modifiable lifestyle factors; and knowing when to refer. It does not attempt to replicate a urology/andrology reference for surgical sperm-retrieval technique, varicocelectomy technique, or a full assisted reproductive technology (ART) protocol — selecting between microsurgical sperm retrieval, IUI, IVF, and intracytoplasmic sperm injection (ICSI) is genuinely specialist decision-making, and this chapter says so plainly rather than fabricating a false sense of completeness in that territory. See the companion Female Infertility chapter for the female-partner workup and treatment ladder, which is not duplicated here.
Recognize the Condition
Three anatomic categories, plus a genuinely common fourth: idiopathic
Once a semen analysis and hormone panel point toward a male factor (see Assessment & Diagnosis), the underlying cause generally sorts by where along the reproductive axis the problem sits — pre-testicular, testicular, or post-testicular — recognizing that a substantial proportion of men are left with no identified cause at all even after a complete workup.[1]
The major etiology categories
Not mutually exclusive, and roughly a third of cases remain idiopathic.
Pre-testicular — hypogonadotropic hypogonadism
A hypothalamic or pituitary problem that fails to drive normal LH/FSH secretion, leaving otherwise-capable testes understimulated. This is the single most genuinely treatable category covered in this chapter — it responds to therapy that stimulates the patient's own gonadotropin axis rather than requiring surgery or ART. Congenital causes include Kallmann syndrome (hypogonadotropic hypogonadism with anosmia) and other isolated GnRH-deficiency syndromes. Acquired causes include a pituitary tumour (particularly a prolactinoma), other pituitary or hypothalamic disease, opioid use, significant obesity, and — a particularly important and increasingly common cause — exogenous androgen or anabolic-androgenic steroid (AAS) use, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis (see Special Populations).
Testicular
A problem intrinsic to the testes themselves, generally presenting with elevated gonadotropins as the pituitary drives, unsuccessfully, a nonresponsive testis. Varicocele is the single most common correctable cause of male infertility, found on exam in roughly 35-40% of men presenting with primary infertility, compared with about 15% of the general male population.[3] Other testicular causes include a history of cryptorchidism (undescended testis); genetic causes — Klinefelter syndrome (47,XXY) is the most common genetic cause of male infertility and is found in a meaningful proportion of men with non-obstructive azoospermia, and Y-chromosome microdeletions are another recognized genetic cause[1]; prior gonadotoxic chemotherapy or radiation; testicular trauma or torsion; and prior orchitis (including mumps orchitis).
Post-testicular — obstructive
Sperm production is normal, but a physical blockage prevents sperm from reaching the ejaculate. Vasectomy is the most common cause overall, simply given how common the procedure itself is. Congenital bilateral absence of the vas deferens (CBAVD) is a less common but important cause, strongly associated with CFTR (cystic fibrosis) gene mutations — a man diagnosed with CBAVD should be referred for genetic counselling given the carrier implications for future children.[1] Other causes include prior epididymitis or another infection causing scarring, and ejaculatory dysfunction (retrograde ejaculation or anejaculation, which can occur with diabetes, spinal cord injury, or certain medications — see Risk Factors).
Idiopathic
A genuinely common outcome — reached when a complete standard workup (semen analysis, hormone panel, physical exam, and any indicated genetic testing) identifies no explanatory abnormality. This is a real diagnosis with its own, more limited, evidence base for empiric therapy, discussed honestly for what the evidence does and does not support (see Choose Initial Treatment), not a diagnosis of exclusion that ends the conversation.
The hormone panel as the key branch point
Serum testosterone, FSH, and LH together sort an abnormal semen analysis into a treatment-relevant pathway more reliably than any single test alone:[1]
- Low or low-normal FSH/LH with low testosterone points to hypogonadotropic hypogonadism (pre-testicular) — the genuinely treatable category this chapter's pharmacotherapy focuses on.
- Elevated FSH/LH with low or low-normal testosterone points to primary testicular failure — the pituitary is appropriately driving a testis that cannot respond; pharmacotherapy aimed at raising gonadotropins further is generally not effective here, and the pathway is specialist-directed (genetic testing, and consideration of surgical sperm retrieval for ART).
- Normal testosterone, FSH, and LH with azoospermia and normal testicular volume points to an obstructive cause — sperm production is intact but blocked, and the pathway is surgical correction or sperm retrieval, specialist-managed.
Clinical presentation
Presentation is simply the couple's account of time spent trying to conceive; the male partner himself is very often asymptomatic. Findings that point toward a specific cause include a palpable scrotal varicocele (a "bag of worms" texture, more prominent standing or with Valsalva), small or soft testes, reduced facial/body hair or gynecomastia (suggesting a hormonal cause), a history of undescended testis, prior groin/scrotal surgery or trauma, or signs of hypogonadism such as reduced libido or erectile dysfunction. Testicular pain or a palpable mass is not a routine infertility-workup finding and warrants urgent urologic evaluation on its own merits (see Red Flags & Refer).
Risk Factors
- Smoking.[4]
- Heavy alcohol use.[4]
- Anabolic-androgenic steroid or exogenous testosterone use — a particularly important and increasingly relevant cause of iatrogenic hypogonadotropic infertility; many patients using these agents for performance or physique reasons have not connected them to fertility risk (see Special Populations).[5]
- Heat exposure — frequent hot tub/sauna use and prolonged direct laptop-on-lap use are reasonable, low-burden counselling points given the testes' temperature sensitivity; evidence for tight underwear and prolonged sitting specifically is weaker but the same principle applies.[4]
- Obesity — associated with lower testosterone and a higher estradiol-to-testosterone ratio from increased peripheral aromatization.[4]
- Certain medications — for example sulfasalazine, cimetidine, some antihypertensives, chemotherapy, and opioids can impair spermatogenesis or suppress the HPG axis; do not stop a needed medication without discussing this with the prescriber first.[2]
- Cryptorchidism history, or prior groin/scrotal surgery, trauma, or testicular torsion.[1]
- Gonadotoxic exposure — chemotherapy, pelvic or testicular radiation, and certain occupational/environmental toxin exposures.[1]
- Cannabis use — evidence is still evolving, but several studies associate regular use with lower sperm concentration and motility; counsel proportionately rather than alarmingly.[4]
- A personal or family history of infertility, or a known genetic condition (e.g., Klinefelter syndrome, cystic fibrosis/CFTR carrier status).[1]
Red Flags & Refer
Refer for formal evaluation — rather than assuming the issue lies with the female partner alone — for any of the following:
- Any couple meeting the standard infertility evaluation criteria (12 months without pregnancy under age 35, or 6 months at age 35 or older) — refer both partners for evaluation, including a semen analysis, from the outset.[2]
- Testicular pain, swelling, or a palpable mass — urgent urologic evaluation to rule out torsion or malignancy; this is not an infertility-workup finding to sit on.
- Signs of hypogonadism — reduced libido, erectile dysfunction, gynecomastia, reduced body/facial hair, or small/soft testes — warrant hormonal workup.
- Azoospermia identified on semen analysis — refer to urology/andrology promptly; timing can matter if surgical sperm retrieval or fertility preservation is being considered.
- A patient using, or with a history of, anabolic-androgenic steroids or exogenous testosterone while trying to conceive — see Special Populations; this deserves direct, non-judgemental counselling and a hormonal workup, not just a lifestyle note.
- A history of cryptorchidism, prior groin/scrotal surgery or trauma, testicular torsion, or gonadotoxic chemotherapy/radiation exposure.
- Any patient facing imminent gonadotoxic treatment who wishes to preserve fertility — refer urgently, before treatment starts, for sperm banking/fertility preservation, mirroring the same urgency as the Female Infertility chapter's fertility-preservation referral.
- A known or suspected genetic condition (e.g., Klinefelter syndrome, or CBAVD/cystic fibrosis carrier status) — refer for genetic counselling given the implications for the patient and future children.[1]
Assessment & Diagnosis
Semen analysis — the cornerstone test
A semen sample, collected after 2-5 days of abstinence, is analyzed against the WHO 6th edition (2021) lower reference limits (5th percentile), based on a reference population of fertile men:[6]
| Parameter | Lower reference limit (5th percentile) |
|---|---|
| Semen volume | 1.4 mL |
| Sperm concentration | 16 million/mL |
| Total motility | 42% |
| Progressive motility | 30% |
| Normal morphology | 4% |
Semen parameters vary substantially between samples from the same man — a single abnormal result should be repeated, typically several weeks later, before being treated as diagnostic; two abnormal analyses carry materially more weight than one.[6]
Hormone panel
Serum testosterone (ideally a morning sample, given diurnal variation), FSH, and LH form the core panel that sorts an abnormal semen analysis by cause (see Recognize the Condition); prolactin is added to help identify a prolactinoma or other pituitary cause when hypogonadotropic hypogonadism is found.[1]
Physical exam
Testicular volume (by orchidometer or ultrasound), varicocele grading (grade I — palpable only with Valsalva; grade II — palpable at rest; grade III — visible at rest), signs of hypogonadism (reduced body/facial hair, gynecomastia), and any prior surgical scarring are assessed as part of the specialist evaluation.[3]
Further specialist-ordered testing
Karyotype (for Klinefelter syndrome and other chromosomal causes), Y-chromosome microdeletion analysis, and CFTR (cystic fibrosis) mutation testing for suspected CBAVD are reserved for severe oligospermia or azoospermia and are ordered by the specialist — not routine community-pharmacy-relevant testing, but useful for a pharmacist to recognize when a patient mentions it.[1][2] Scrotal ultrasound may be used when the physical exam is equivocal for varicocele, or to rule out a testicular mass.
Treatment Targets
- Identify and treat a modifiable or reversible cause where one exists — for example, discontinuing exogenous testosterone/anabolic-androgenic steroids, treating hyperprolactinemia, or correcting a varicocele — rather than proceeding straight to assisted reproduction for every patient.
- For confirmed hypogonadotropic hypogonadism specifically, restore endogenous LH/FSH-driven testosterone production and spermatogenesis using therapy that stimulates rather than replaces the HPG axis.
- In categories that are not directly reversible, optimize fertility potential and support informed decision-making about surgical sperm retrieval and assisted reproductive technology where appropriate.
- Reinforce genuinely modifiable lifestyle factors as adjuncts to, not substitutes for, appropriate specialist care.
- Recognize where specialist (urology/andrology, or reproductive endocrinology) expertise is required, and refer promptly rather than attempting to manage specialist-level decisions from the pharmacy.
- Provide non-judgemental counselling — male infertility carries a real and under-recognized psychological burden, including for a man whose infertility relates to his own prior anabolic steroid use.
Choose Initial Treatment
Before starting any hormonal pharmacotherapy, confirm there is not a directly reversible cause: discontinue exogenous testosterone or anabolic-androgenic steroids if the patient is using them (see Special Populations for the HPG-axis recovery timeline and the hCG/FSH-based recovery protocol), treat hyperprolactinemia or another identified pituitary problem, address a contributing medication in coordination with the prescriber, and reinforce modifiable lifestyle factors (see Non-Pharmacologic Treatment).
Once hypogonadotropic hypogonadism is confirmed (low or low-normal FSH and LH with low testosterone; see Assessment & Diagnosis) and its own underlying cause has been evaluated, clinicians may use a selective estrogen receptor modulator (clomiphene), an aromatase inhibitor (letrozole or anastrozole), human chorionic gonadotropin (hCG), or a combination of these — a conditional recommendation supported by evidence graded C.[7] All work the same general way: they raise endogenous LH and FSH, which in turn raises intratesticular testosterone to the very high local concentration spermatogenesis actually requires — a fundamentally different mechanism from, and one that is undermined by, exogenous testosterone (see the callout below).
Often tried first Clomiphene citrate — blocks estrogen's negative feedback at the hypothalamus/pituitary, increasing GnRH pulsatility and downstream LH/FSH; the most-studied SERM for this indication, with meta-analysis data showing improved testosterone, gonadotropin levels, and semen parameters in hypogonadal men, and pregnancy achieved during treatment in a meaningful minority of couples.[8]
Alternative Letrozole or anastrozole (aromatase inhibitors) — block peripheral conversion of testosterone to estradiol, which both raises testosterone directly and reduces estrogen's negative feedback on the pituitary; a particularly rational choice when obesity is contributing, since adipose tissue is a major site of aromatization and obesity itself raises the estradiol-to-testosterone ratio.[7]
Add-on, or for more significant HH Human chorionic gonadotropin (hCG) — a direct LH analogue that stimulates Leydig-cell testosterone production; often added to, or used instead of, clomiphene/an aromatase inhibitor for more significant hypogonadotropic hypogonadism, typically trialled for several months before assessing response.[7]
Add-on if spermatogenesis is inadequate on hCG alone FSH (follitropin alfa or menotropins) — added when spermatogenesis has not returned adequately after an adequate hCG trial, since FSH provides direct Sertoli-cell stimulation that hCG/LH activity alone does not fully replace.[7]
Not the same as idiopathic infertility In a man with normal testosterone, FSH, and LH (idiopathic infertility — no hypogonadotropic pattern), the evidence for these same agents is materially weaker; inform the patient that SERM therapy has limited benefit relative to proceeding directly to ART in this scenario, rather than presenting it as an equivalent alternative.[7]
For a clinically palpable varicocele with an abnormal semen analysis and no other identified explanation, varicocele repair — microsurgical subinguinal varicocelectomy is the current reference standard, with percutaneous embolization as an alternative — is the primary treatment and can improve semen parameters and pregnancy rates.[3] Procedure selection and candidacy assessment are entirely urology-directed; the pharmacist's role is understanding that this is the primary, guideline-supported treatment for varicocele-associated infertility so a patient's referral makes sense to them, not managing the surgical decision itself.
Vasectomy reversal, surgical correction of another identified obstruction, or surgical sperm retrieval (e.g., testicular sperm extraction/micro-TESE, or percutaneous epididymal sperm aspiration) paired with ICSI are the treatment options for a confirmed obstructive cause, individualized to the specific obstruction, its duration, and the couple's preferences — entirely urology/andrology-directed decision-making that this chapter does not attempt to reproduce.
For male-factor infertility that persists despite the above, or that is severe from the outset, a reproductive endocrinology and infertility (REI) specialist may recommend intrauterine insemination (IUI, for a mild male factor), in vitro fertilization (IVF), or IVF with intracytoplasmic sperm injection (ICSI) — in which a single sperm is injected directly into an egg, making pregnancy possible even with very severe oligospermia or surgically retrieved sperm. Protocol selection is entirely specialist-directed; this chapter's role is accurately explaining to a patient what these options broadly involve while directing the actual decision-making back to their REI specialist, matching how the companion Female Infertility chapter treats the same ART territory.
Non-Pharmacologic Treatment
- Discontinuing anabolic-androgenic steroid or exogenous testosterone use — the single highest-yield lifestyle-category intervention for a patient using these agents; counsel that HPG-axis recovery is variable and can take many months, and that hCG/FSH-based therapy can shorten and support recovery (see Special Populations) rather than simply waiting it out.[5]
- Smoking cessation — smoking is associated with reduced sperm concentration and motility; cessation support is a genuinely high-yield pharmacist-led intervention.[4]
- Alcohol moderation — heavy alcohol use is best avoided while trying to conceive.[4]
- Heat-exposure reduction — limiting frequent hot tub/sauna use and prolonged direct laptop-on-lap use is a reasonable, low-burden counselling point given the testes' temperature sensitivity.[4]
- Weight optimization — obesity is associated with lower testosterone and a higher estradiol-to-testosterone ratio through increased peripheral aromatization.[4]
- Reducing cannabis and other recreational drug use — reasonable to raise as a modifiable factor, proportionate to the more limited evidence base compared with smoking/alcohol.[4]
- Psychosocial support — male infertility carries a genuine and often under-recognized psychological burden, including for a patient whose infertility is linked to his own past anabolic steroid use; approach every conversation without judgement and offer or refer for counselling support.
Pharmacologic Treatment Options
| Drug / intervention | Role | Dose / use | Important adverse effects | Teaching points |
|---|---|---|---|---|
| Clomiphene citrate Often tried first | Off-label SERM for confirmed hypogonadotropic hypogonadism | 12.5-50 mg PO once daily or every other day (off-label; substantially lower than female ovulation-induction doses) | Hot flashes, mood changes, visual disturbances (stop if these occur) | Confirmed hypogonadotropic hypogonadism only — limited benefit in a man with normal testosterone/FSH/LH. No Pharmasist Drug Database monograph currently exists for this agent. |
| Letrozole Alternative | Off-label aromatase inhibitor for confirmed hypogonadotropic hypogonadism | 2.5 mg PO once daily, or dosed less frequently in some protocols (off-label; dosing is less standardized than female ovulation-induction use) | Hot flashes, fatigue, headache, joint aches | Same repurposed off-label agent used for female ovulation induction, at a different dose/frequency and for a different mechanism-driven indication here. |
| Anastrozole Alternative | Off-label aromatase inhibitor, particularly when obesity/elevated estradiol is contributing | 1 mg PO once daily, or dosed less frequently (e.g., twice weekly) in some protocols (off-label) | Hot flashes, joint aches, headache | A rational choice when the testosterone-to-estradiol ratio suggests excess peripheral aromatization, e.g., in obesity. |
| Human chorionic gonadotropin (hCG) Add-on / more significant HH | LH analogue — stimulates Leydig-cell testosterone production | 1,500-5,000 IU SC/IM 2-3 times weekly, typically trialled for several months before assessing response | Injection-site reactions, gynecomastia (from increased peripheral aromatization of the testosterone it generates), mood changes | Sustains the very high intratesticular testosterone concentration spermatogenesis requires — the opposite effect of exogenous testosterone. |
| FSH (follitropin alfa or menotropins) Add-on if hCG alone is inadequate | Direct Sertoli-cell stimulation, added when spermatogenesis has not returned on hCG alone | 75-150 IU SC 2-3 times weekly, added after an adequate hCG trial | Injection-site reactions, headache | Recombinant FSH (follitropin alfa) or human-derived FSH/LH activity (menotropins) are both used; selection and titration are specialist-directed. |
Special Populations
Anabolic-androgenic steroid (AAS) or exogenous testosterone use
Elevated circulating androgens suppress GnRH, LH, and FSH secretion through negative feedback even at modest supraphysiologic doses, producing an iatrogenic hypogonadotropic hypogonadism that can range from reduced sperm counts to complete azoospermia.[5] Recovery after stopping is genuinely variable: biochemical (hormonal) recovery often occurs faster than recovery of semen parameters, and while most men who used AAS for under a year recover HPG-axis function within about a year of stopping, prolonged or high-dose use is associated with delayed or incomplete recovery in a clinically meaningful subset.[5] For a man who has not recovered spontaneously in the expected timeframe, combination hCG-plus-FSH therapy over roughly 12-24 months has been associated with testicular growth in almost all patients, restored spermatogenesis in around 80%, and pregnancy in around 50% — genuinely encouraging figures worth sharing with a patient who assumes the damage is permanent.[5] Approach this conversation without judgement: many patients using performance-enhancing drugs have simply never connected the exposure to their fertility.
Klinefelter syndrome and other genetic causes
Klinefelter syndrome (47,XXY) is the most common genetic cause of male infertility and is found in a meaningful proportion of men with non-obstructive azoospermia; Y-chromosome microdeletions are another recognized cause identified on specialist-ordered genetic testing.[1] These are primary testicular causes (elevated FSH/LH) rather than hypogonadotropic ones, so the pharmacotherapy detailed in Choose Initial Treatment is not expected to help — the pathway is specialist-directed, sometimes including surgical sperm retrieval for ART with genetic counselling for the couple.
Fertility preservation before gonadotoxic treatment
Any patient facing imminent chemotherapy, pelvic/testicular radiation, or another fertility-threatening treatment should be referred urgently — ideally before treatment starts — for sperm banking/fertility preservation. This is time-sensitive specialist territory; the pharmacist's role is recognizing the situation and prompting an urgent referral rather than delaying it to complete routine counselling, mirroring the same urgency in the companion Female Infertility chapter.
CBAVD and cystic fibrosis carrier status
Congenital bilateral absence of the vas deferens is strongly associated with CFTR gene mutations. A man diagnosed with CBAVD, and his partner, should be referred for genetic counselling and CFTR carrier testing before pursuing surgical sperm retrieval and ART, given the implications for a future child's cystic fibrosis risk.[1]
Couples pursuing assisted reproduction together
See the companion Female Infertility chapter for the female-partner workup and treatment ladder (ovulation induction, gonadotropin cycles, luteal support), which is not duplicated here — the two chapters are intended to be read together for a couple undergoing a combined evaluation.
Monitoring & Follow-Up
During clomiphene, letrozole/anastrozole, or hCG therapy
Follow-up bloodwork (testosterone, estradiol, FSH, LH) is typically checked periodically per the prescriber's own protocol. Spermatogenesis takes roughly three months (about 74 days) from a stimulus to mature, ejaculated sperm, so a repeat semen analysis obtained sooner than about three months into therapy is not meaningfully informative — set this expectation with the patient up front.[7] Ask about gynecomastia (a recognized effect of hCG-driven aromatization) and mood or visual changes (clomiphene) at refills; both warrant a call back to the prescriber rather than the patient simply stopping therapy on their own.
Complications to watch for
An untreated, clinically significant varicocele is associated with a progressive decline in semen parameters and testicular volume over time, which is part of why timely referral — rather than prolonged watchful waiting once one is identified — is reasonable.[3] The psychosocial burden of unresolved infertility, described above, is itself a genuine complication worth proactively asking about. Medication-specific adverse effects are summarized in the drug table.
Longitudinal follow-up
For a patient who has met the standard evaluation trigger but not yet completed a specialist workup, follow up on whether the referral was actually completed rather than assuming it was. For a patient already established with a urologist/andrologist or an REI specialist, keep pharmacy counselling complementary to, not duplicative of, the specialist's own monitoring plan.
Treatment Failure / Next Step
- No meaningful improvement in hormone levels or semen parameters after an adequate trial (commonly around 3-6 months, respecting the spermatogenic cycle) of clomiphene or an aromatase inhibitor: the prescriber may add or switch to hCG, or add FSH if hCG alone is insufficient.[7]
- Confirmed primary testicular failure (elevated FSH/LH): refer to urology/andrology rather than continuing gonadotropin-axis-stimulating therapy, which is not expected to help when the problem is at the testis rather than the pituitary.
- Confirmed obstructive azoospermia: refer for surgical correction or sperm retrieval plus ICSI rather than trialling hormonal therapy, which does not address a mechanical blockage.
- AAS-induced hypogonadotropic hypogonadism without recovery in the expected timeframe after cessation: refer to endocrinology/andrology for hCG/FSH-based induction therapy rather than open-ended waiting.[5]
- A clinically significant varicocele with abnormal semen parameters and no better explanation: refer for surgical evaluation rather than trialling hormonal therapy, which does not treat a varicocele.[3]
- Persistent infertility despite an adequate, appropriately targeted pharmacotherapy trial: refer for the specialist-directed ART pathway (IUI/IVF/ICSI) rather than continuing hormonal therapy indefinitely.
Common Errors to Avoid
- Assuming infertility is a female-only issue and delaying a semen analysis until the female workup is "exhausted."
- Prescribing or continuing exogenous testosterone therapy in a man who is trying to conceive, or failing to ask about testosterone/anabolic steroid use when a patient presents with infertility.
- Using clomiphene, an aromatase inhibitor, or hCG in a man with normal testosterone/FSH/LH (true idiopathic infertility) with the same confidence as in confirmed hypogonadotropic hypogonadism — the evidence base is materially different.
- Treating a single abnormal semen analysis as definitive without a repeat test, given substantial natural sample-to-sample variability.
- Expecting a semen-parameter improvement within days to weeks of starting hormonal therapy — spermatogenesis takes roughly three months, so meaningful reassessment needs to wait that long.
- Treating "idiopathic infertility" as a dead end rather than a genuine diagnosis with its own, more limited, evidence-based options and a clear specialist-directed pathway.
- Missing the counselling opportunity with a patient using performance-enhancing anabolic steroids who has not connected that use to his own fertility.
- Attempting to independently manage a varicocele, obstructive azoospermia, or genetic-cause workup from the pharmacy rather than referring to urology/andrology.
- Using judgemental language with a patient whose infertility relates to his own prior substance use, rather than offering non-judgemental, practical counselling.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are off-label adult doses specific to confirmed hypogonadotropic hypogonadism and require patient-specific, and often specialist-protocol-specific, confirmation — none of these agents carries a Health Canada-approved indication for male infertility. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Off-Label Ovulation-Induction-Class Agents — Confirmed Hypogonadotropic Hypogonadism
First-tried and alternative oral agents. Materially weaker evidence applies to a man with normal testosterone/FSH/LH (idiopathic infertility) than to confirmed hypogonadotropic hypogonadism.[7]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Clomiphene citrate | 12.5-50 mg PO once daily or every other day (off-label; substantially lower than female ovulation-induction doses) | Hot flashes, mood changes, visual disturbances (stop if these occur) | None significant at these off-label doses | The most-studied SERM for this indication; meta-analysis data show improved testosterone, gonadotropin levels, and semen parameters, with pregnancy achieved during treatment in a meaningful minority of couples. No Pharmasist Drug Database monograph currently exists for this agent.[8] |
| Letrozole | 2.5 mg PO once daily, or dosed less frequently in some protocols (off-label; dosing is less standardized than female ovulation-induction use) | Hot flashes, fatigue, headache, joint aches | None significant at these off-label doses | Same repurposed off-label agent used for female ovulation induction, at a different dose/frequency and mechanism-driven indication here — blocks peripheral aromatization of testosterone to estradiol.[7] |
| Anastrozole | 1 mg PO once daily, or dosed less frequently (e.g., twice weekly) in some protocols (off-label) | Hot flashes, joint aches, headache | None significant at these off-label doses | A rational choice when the testosterone-to-estradiol ratio suggests excess peripheral aromatization, e.g., in obesity.[7] |
Gonadotropins — Confirmed Hypogonadotropic Hypogonadism, Specialist-Initiated
Used alone or added to an oral agent when response is inadequate; also the basis of the recovery protocol for anabolic-steroid-induced hypogonadism (see Special Populations).[5]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Human chorionic gonadotropin (hCG) | 1,500-5,000 IU SC/IM 2-3 times weekly, typically trialled for several months before assessing response | Injection-site reactions; gynecomastia from increased peripheral aromatization of the testosterone it generates; mood changes | None significant beyond the induction protocol itself | A direct LH analogue — sustains the very high intratesticular testosterone concentration spermatogenesis requires, the opposite effect of exogenous testosterone.[7] |
| FSH (follitropin alfa or menotropins) | 75-150 IU SC 2-3 times weekly, added after an adequate hCG trial if spermatogenesis has not returned | Injection-site reactions, headache | None significant beyond the induction protocol itself | Recombinant FSH (follitropin alfa) or human-derived FSH/LH activity (menotropins, an alternative) provide direct Sertoli-cell stimulation that hCG/LH activity alone does not fully replace.[7] |
Evidence note: varicocele repair, surgical correction or retrieval for obstructive causes, and full ART/ICSI protocol selection are specialist-managed and intentionally not detailed as dosed interventions in this table — see Choose Initial Treatment for why.
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.